# Uwe Platzbecker

Source: https://onco.cc/people/uwe-platzbecker/  
OnCo record `uwe-platzbecker` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led MEDALIST and COMMANDS, which made luspatercept a first-line treatment for anaemia in lower-risk MDS.

## Summary

Uwe Platzbecker (Leipzig) was a principal investigator of MEDALIST and led COMMANDS, the trials establishing luspatercept for transfusion-dependent anaemia in lower-risk myelodysplastic syndromes, first after and then instead of erythropoiesis-stimulating agents. He coordinates the German MDS Study Group and the European MDS registry and has led trials of hypomethylating agent combinations in higher-risk disease.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: mds; anaemia; trialist
- Role: Director, Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital Leipzig
- Specialisms: Myelodysplastic syndromes; Anaemia therapeutics; Acute myeloid leukaemia; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Platzbecker%20U%5BAuthor%5D%20luspatercept%20MDS

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- institutions: [Leipzig University Hospital / University Cancer Center Leipzig (UCCL)](https://onco.cc/institutions/university-hospital-leipzig/)
- key papers: [COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions](https://onco.cc/key-papers/paper-commands-luspatercept-mds-lancet-2023/)
- trials: [COMMANDS](https://onco.cc/trials/commands/), [IMerge](https://onco.cc/trials/imerge/)

---
JSON: https://onco.cc/api/v1/entities/uwe-platzbecker.json